MLICM
DRNA

Metropolitan Life Insurance Company (MetLife)’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,238
Closed -$408K – 2866
2021
Q3 		$408K Hold
20,238
– – 0.01% 1585
2021
Q2 		$755K Buy
20,238
+829
+4% +$25.4K 0.01% 1226
2021
Q1 		$496K Sell
19,409
-641
-3% -$16.4K 0.01% 1413
2020
Q4 		$442K Hold
20,050
– – 0.01% 1436
2020
Q3 		$361K Hold
20,050
– – 0.01% 1430
2020
Q2 		$509K Buy
20,050
+1,940
+11% +$41.8K 0.01% 1181
2020
Q1 		$333K Hold
18,110
– – 0.01% 1295
2019
Q4 		$399K Hold
18,110
– – 0.01% 1467
2019
Q3 		$260K Hold
18,110
– – ﹤0.01% 1695
2019
Q2 		$285K Buy
18,110
+879
+5% +$12K ﹤0.01% 1655
2019
Q1 		$252K Sell
17,231
-1,238
-7% -$14.2K ﹤0.01% 1747
2018
Q4 		$197K Buy
18,469
+3,136
+20% +$41.2K ﹤0.01% 1828
2018
Q3 		$234K Hold
15,333
– – ﹤0.01% 1896
2018
Q2 		$188K Buy
+15,333
New +$193K ﹤0.01% 1983
2016
Q1 		– Sell
-11,866
Closed -$141K – 2540
2015
Q4 		$141K Buy
+11,866
New +$136K ﹤0.01% 2459

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.76B AUM 40.74% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s DRNA Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 20,238 shares — an estimated $408K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in DRNA in Q4 2015 and held it in 15 quarters. The position peaked at $755K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 20,238 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $408K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2015 and held it in 15 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Dicerna Pharmaceuticals, Inc. position peaked at $755K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.